COVID-19 accelerates the progression of atherosclerotic plaques, increasing coronary inflammation and the risk of high-risk ...

To see how the coronavirus that causes COVID-19, SARS-CoV-2, might affect coronary arteries that supply blood to the heart, ...

Hereditary high cholesterol (FH) is the most common hereditary disease and, if left untreated, can lead to atherosclerosis, ...

The most common cardiovascular killer in maternal medicine is also among the most misdiagnosed. Peripartum cardiomyopathy ...

The artificial intelligence model predicts patients’ heart disorders and risk of future heart failure using just an ...

The blood pressure study could help doctors treating people with diabetes to reduce the risk of "major cardiovascular events" ...

These findings support more aggressive blood pressure management for people with Type 2 diabetes to reduce their risk of ...

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Diabetic cardiomyopathy (DCM) is a specific type of cardiomyopathy that is independent of hypertension and ...

In the first 22 months of a mavacamten REMS program, few patients needed a temporary interruption in treatment for LVEF below 50%.

This research highlights the importance of rethinking current blood pressure guidelines for diabetes patients. Lowering ...

The approval covers dosages of 24 mg/26 mg, 49 mg/51 mg and 97 mg/103 mg. They are also used for treating symptomatic heart ...

JK-07 is under clinical development by Salubris Biotherapeutics and currently in Phase II for Diastolic Heart Failure (HFpEF). According to GlobalData, Phase II drugs for Diastolic Heart Failure ...